hypophosphatemia%20-and-%20hyperphosphatemia
HYPOPHOSPHATEMIA & HYPERPHOSPHATEMIA

Hypophosphatemia is an electrolyte imbalance where there is a decrease in the serum phosphate level that is less than the normal range.

It is recognized most often in critically-ill patients, decompensated diabetics, alcoholics or other malnourished persons, and acute infectious or pulmonary disorders.

It may be transient and reflect intracellular shift with minimal clinical consequences.

Hyperphosphatemia is an electrolyte disturbance in which an increase in the serum phosphate level of more than the normal range is present.

Most symptoms of acute hyperphosphatemia are due to secondary hypocalcemia.

The significant level of hyperphosphatemia in adults is >6 mg/dL.

Hypophosphatemia%20-and-%20hyperphosphatemia Diagnosis

Diagnosis

Hypophosphatemia
  • A decrease in serum phosphate should be distinguished from a decrease in total body storage of phosphate (phosphate deficiency)
  • The extracellular fluid contains <5% of total body phosphorus
  • Depending on renal function, serum phosphate may be normal or high in profound intracellular deficiency
  • Serum phosphate may be low even when intracellular phosphate is normal following a sudden movement of extracellular phosphate
Hyperphosphatemia
  • Normal adult range: 2.45-4.5 mg/dL (0.81-1.45 mmol/L)

Classification

Mild Hypophosphatemia
  • Patient is usually asymptomatic
  • Serum phosphate 0.75-1.0 mmol/L (2.2-3 mg/dL)
Moderate Hypophosphatemia
  • Usually asymptomatic
  • Serum phosphate 0.5-0.7 mmol/L (1.5-2.2 mg/dL)
Severe Hypophosphatemia
  • Patient is usually symptomatic
  • Serum phosphate <0.3-0.5 mmol/L (<1-1.5 mg/dL)

Evaluation

  • Hypophosphatemia may be transient and reflect intracellular shift with minimal clinical consequences
  • In most cases of intracellular shift of phosphate, serum phosphate normalizes once the cause is managed

Conditions that accelerate intracellular uptake of phosphate

  • Any cause of hyperventilation (eg sepsis, anxiety, pain, etc)
  • Intravenous (IV) glucose administration
  • Insulin therapy
  • Administration of catecholamines and beta-receptor agonists
  • Leukemic blast crisis
  • Administration of erythropoietin or GCS-F
  • Postsurgery or after trauma
  • Thyrotoxic periodic paralysis
Conditions that decrease intestinal absorption of phosphate
  • Severe deprivation of dietary phosphate
  • Chronic diarrhea and steatorrhea
  • Vitamin D deficiency and resistance
  • Phosphate absorption inhibition caused by antacids, phosphate binders, niacin
Conditions that can cause increased urinary excretion
  • Hyperparathyroidism
  • Vitamin D deficiency and resistance
  • Hypophosphatemic rickets that is hereditary
  • Oncogenic osteomalacia
  • Fanconi syndrome
  • Use of Acetazolamide, Tenofovir, Iron (IV), chemotherapeutic agents

Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients

  • Patients with CKD has elevated risk in having hyperphosphatemia
  • In the early stages of CKD, there is a gradual decrease in filtered phosphate load that causes phosphate retention
  • The retention of phosphate stimulates fibroblast growth factor-23 (FGF-23) and parathyroid hormone (PTH) secretion, that causes increased renal fractional excretion of phosphate by decreasing tubular phosphate reabsorption
  • Production of dihydroxyvitamin D is suppressed by FGF-23, thereby decreasing intestinal phosphate absorption which causes elevated PTH levels, resulting in the development of secondary hyperparathyroidism
  • The continued decline in renal function causes development of hyperphosphatemia due to insufficient renal excretion despite high levels of PTH and FGF-23
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
28 Apr 2020
Women who skip breakfast before and during early pregnancy have a higher risk of developing gestational diabetes mellitus (GDM) than those who have the essential meal daily, suggests a study.
Pearl Toh, 23 Sep 2020
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, 23 Sep 2020

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.